/Does blinatumomab reduce the Myasthenia Gravis Activities of Daily Living (MG-ADL) score compared to baseline at 6 months in refractory myasthenia gravis patients?
Research Question
Does blinatumomab reduce the Myasthenia Gravis Activities of Daily Living (MG-ADL) score compared to baseline at 6 months in refractory myasthenia gravis patients?
2026